A Greener Way to Grow
 | | A Message From Med-x Inc: |  | | Med-X Gearing Up For a Possible NASDAQ Listing (Ticker: MXRX) But the Real Opportunity is Now – Before They Hit the Big Stage
In certain use cases, their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.
The global biopesticide market is expected to grow ~3X by 2030, from $5.8 billion in 2022 to an impressive $17.6 billion by 20301. Med-X expects pesticide bans and other regulatory actions around the world to fuel their vision of Nature-Cide as the world's leading "clean" pest control product.
Its plant-based formulation not only prioritizes safety, but delivers industrial-grade results, challenging long-held assumptions about what natural products can achieve in professional settings.
NASDAQ Ticker: MXRX Reserved!
The Real Opportunity to Become a Shareholder is Now!
Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, and the agricultural sectors. Proudly produced in the USA under strict quality standards, Nature-Cide reflects their commitment to sustainable pest management innovation.
Med-X products are already available through e-commerce giants like Walmart, Amazon, and Kroger, and they plan to expand internationally.
With $6.4M in sales in just four years, expanding to 41 international markets, Med-X is getting ready for the next step...
Simpler, Safer, More Effective Pesticides
Become A Med-X Shareholder At $4 Per Share Before Their NASDAQ Plans Unfold | | | | Disclosures: This is a paid advertisement for Med-X's Regulation A+ Offering.
Please read the offering circular at invest.medx-rx.com 1. Vantage Market Research - www.vantagemarketresearch.com/industry-report/biopesticides-market-1854
This message is a paid advertisement for Med-x Inc. via Investing Media Solutions. Schaeffer's Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer's Investment Research Inc. and its principals are not affiliated with Med-x Inc. Schaeffer's Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer's Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer's Investment Research Inc. to buy or sell any security. Schaeffer's Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer's Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Med-x Inc. on the Med-x Inc. website for additional information. | | | | |
0 Response to "IPO Alert: MXRX Planning To List On The Nasdaq"
Post a Comment